{"url_path":"/sec/vrdn/8-k/2026-06-29/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-29","source_url":"https://www.sec.gov/Archives/edgar/data/1590750/0001193125-26-286273-index.html","accession_number":"0001193125-26-286273","cik":"0001590750","ticker":"VRDN","issuer_name":"Viridian Therapeutics, Inc.\\DE","edgar_url":"https://www.sec.gov/Archives/edgar/data/1590750/0001193125-26-286273-index.html","primary_entity_key":"0001590750","primary_entity_name":"Viridian Therapeutics, Inc.\\DE"},"word_count":76,"has_tables":true,"body_markdown":"Item 9.01\n\nFinancial Statements and Exhibits.\n\n(d) Exhibits.\n\n \n\n99.1\n  \n[Press Release, dated June 26, 2026](d164211dex991.htm)\n\n104\n  \nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \nViridian Therapeutics, Inc.\n\nDate: June 29, 2026\n \n\n \nBy:\n \n\n/s/ Stephen Mahoney\n\n \n\n \n\n \nStephen Mahoney\n\n \n\n \n\n \nPresident and Chief Executive Officer"}